Evidence map›Paper›PMID 42486098›Full record

ArticleCell reports. Medicine2026

Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy.

Lei Yao, Deze Zhao, Yu Meng, Yihuang Liu, Hui Su, Danyao Chen, Ziyu Guo, Daishi Li, Linfeng Li, Qian Zhou and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lei YaoDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China; Department of Hepatic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; National Clinical Research Center of Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China.
Deze ZhaoDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China; Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; National Clinical Research Center of Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China.
Yu MengDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China; Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha 410008, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Central South University, Changsha 410008, China; National Clinical Research Center of Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China; Hu Nan Key Laboratory of Aging Biology, Changsha 410008, China.
Yihuang LiuDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China.
Hui SuDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China; Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha 410008, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Central South University, Changsha 410008, China.
Danyao ChenDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China; Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Ziyu GuoDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China; Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha 410008, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Central South University, Changsha 410008, China.
Daishi LiDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China; Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha 410008, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Central South University, Changsha 410008, China.
Linfeng LiDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China; Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Qian ZhouDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China; Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha 410008, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Central South University, Changsha 410008, China; National Clinical Research Center of Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China; Hu Nan Key Laboratory of Aging Biology, Changsha 410008, China.
Shengchao XuDepartment of Neurosurgery, Xiangya Hospital, Central South University, No.87, Xiangya Road, Changsha, Hunan 410008, China.
Furong ZengNational Clinical Research Center of Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China; Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan Province 410008, China. Electronic address: zengflorachn@hotmail.com.
Xiang ChenDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China; Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha 410008, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Central South University, Changsha 410008, China; National Clinical Research Center of Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China; Hu Nan Key Laboratory of Aging Biology, Changsha 410008, China. Electronic address: chenxiangck@126.com.
Ledu ZhouDepartment of Hepatic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; National Clinical Research Center of Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China. Electronic address: zhould@csu.edu.cn.
Guangtong DengDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha 410008, China; Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha 410008, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Central South University, Changsha 410008, China; National Clinical Research Center of Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China; Hu Nan Key Laboratory of Aging Biology, Changsha 410008, China. Electronic address: dengguangtong@outlook.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy efficacy is limited by poor tumor immunogenicity and insufficient immune infiltration, highlighting the critical role of inducing immunogenic cell death for improved outcomes. Targeting cuproptosis holds promising therapeutic potential, but its immunogenic and capacity to stimulate anti-tumor immunity to potentiate immunotherapy remains unknown. Through screening of 240 Food and Drug Administration (FDA)-approved anti-tumor drugs, we identify nilotinib as a potent cuproptosis inducer in cancer cells, especially at physiologically relevant copper concentrations. Mechanistically, nilotinib-copper elicits cuproptosis in vitro and in vivo by repressing the copper exporter ATP7A via ETV1 to drive mitochondrial copper accumulation and activating mitogen-activated protein kinase (MAPK) pathway through ERK2 phosphorylation. Preclinically, nilotinib-copper induces immunogenic cuproptosis and enhances anti-PD-1 efficacy across multiple melanoma models, including B16F10 tumor-bearing mice, Braf/Pten-driven spontaneous melanoma mice, and PBMC-humanized mice. Clinically, the ATP7A

Indexed as

CuproptosisImmunotherapyPyrimidinesAnimalsCell Line, TumorCopper-Transporting ATPasesHumansMelanoma, ExperimentalMiceMice, Inbred C57BLCopper-Transporting ATPasesnilotinibPyrimidinesATP7Acancer immunotherapycuproptosisimmunogenic cell deathnilotinib

Identifiers

PMID42486098
PMCPMC13522801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.